Valuation: CorMedix Inc.

Market Cap 686M 600M 551M 514M 975M 65.36B 990M 6.62B 2.57B 32.13B 2.58B 2.52B 111B P/E 2026 *
17.5x
P/E 2027 * 102x
Enterprise Value 686M 600M 551M 514M 975M 65.36B 990M 6.62B 2.57B 32.13B 2.58B 2.52B 111B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 2.41x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day+3.31%
1 week+11.46%
Current month+11.46%
1 month+4.67%
3 months+24.11%
6 months-28.22%
Current year-24.76%
1 week 7.58
Extreme 7.58
8.84
1 month 7.5
Extreme 7.495
9.09
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-09
Director of Finance/CFO 54 2025-08-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 67 2015-08-05
Chairman 81 2017-08-02
Director/Board Member 70 2011-08-15
Date Insider Type Main position Quantity % Market Cap.
02-03Free

General Counsel

36,006 0.0457%
02-03Free

Chief Executive Officer

77,156 0.0979%
02-03Free

Chief Operating Officer

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%+11.46%-24.70%+137.13% 686M
+3.34%+0.70%+60.09%+13.95% 320B
-1.25%0.00%+30.92%-2.05% 72.44B
+3.17%+5.99%+47.13%+117.91% 9.42B
+1.82%+5.32%+8.41%+2.40% 8.65B
+8.48%+25.95%+25.73%+34.01% 4.52B
-0.46%+3.98%-5.69%+9.39% 4.41B
+0.43%+6.02%-33.90%+25.93% 3.43B
+1.35%+2.58%+50.25%+62.72% 2.79B
-1.28%+7.61%+15.27%-22.32% 2.19B
Average +1.90%+4.12%+17.35%+37.91% 42.85B
Weighted average by Cap. +2.49%+2.86%+51.61%+13.89%

Financials

2026 *2027 *
Net sales 334M 292M 268M 250M 475M 31.81B 482M 3.22B 1.25B 15.64B 1.25B 1.23B 53.88B 285M 249M 229M 213M 405M 27.14B 411M 2.75B 1.07B 13.34B 1.07B 1.05B 45.97B
Net income 46.78M 40.89M 37.58M 35.03M 66.44M 4.45B 67.45M 451M 175M 2.19B 176M 172M 7.54B 8.47M 7.41M 6.81M 6.35M 12.04M 807M 12.22M 81.73M 31.77M 397M 31.81M 31.12M 1.37B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
26-07-02 US$8.750 +3.31% 1,043,904
26-07-01 US$8.470 +7.90% 1,277,023
26-06-30 US$7.850 +2.75% 1,359,905
26-06-29 US$7.640 -2.68% 1,283,598
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.750USD
Average target price
15.20USD
Spread / Average Target
+73.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock